Therapeutic alternatives for chronic urticaria: additional reports on omalizumab.
Spector
Sheldon L
SL
Tan
Ricardo A
RA
D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002908:Chronic Disease; D004334:Drug Administration Schedule; D006801:Humans; D000069444:Omalizumab; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy*
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab